The Amadorins inhibit AGE formation at its earliest stages. By interrupting the pathway at the first step of oxidative breakdown, Amadorins offer the greatest promise of protection against the myriad of diseases driven by AGEs accumulation and Oxidative Stress. 



diagram of Praetego's pipeline process



Praetego’s candidates are called ‘Amadorins’. These proprietary small molecules are unique inhibitors of the oxidative breakdown of proteins modified by glucose (Amadori products). This non-enzymatic process forms byproducts called Advanced Glycation End-products, or AGEs. AGE formation and accumulation lead to diabetic microvascular disease. AGE pathology is also active in cardiovascular disease, neurodegeneration, and many chronic diseases of aging.

The Amadorins have been developed and tested over 4 generations. The latest series of novel candidates offer the greatest potency and margin of safety in nonclinical testing. Praetego has filed for patent protection of this series. The lead candidate, PTG-6 comes from this series.


Diabetic Peripheral Neuropathy (DPN)

Our lead indication is Diabetic Peripheral Neuropathy (DPN)—a degenerative process of the nerves, often starting in the extremities. Affecting approximately 50% of diabetics, DPN can be very painful. It can also lead to foot ulcers and amputations. Praetego’s Amadorins mitigate an underlying cause of the damage.

In proof of concept studies using a standard animal model of DPN, all Amadorins tested restored nerve function. They reversed nerve deficits in both large and small nerve fibers. Across the Amadorins tested, we confirmed that stronger AGE inhibition meant greater potency.

PTG-6 has demonstrated optimal potency as an AGE inhibitor. It is demonstrating neuroprotective and neurorestorative effects in the animal model of DPN.  In preclinical safety studies, PTG-6 demonstrated a wide therapeutic window and minimal off-target hits.

Our current drug development work is funded by the National Institute of Diabetic and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).


Other Indications

Beyond DPN, we are developing PTG-6 for Diabetic Retinopathy, Nephropathy, and Neurodegeneration / Alzheimer’s Disease.